Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,644,560
  • Shares Outstanding, K 37,075
  • Annual Sales, $ 0 K
  • Annual Income, $ -68,350 K
  • 60-Month Beta 3.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.54
  • Number of Estimates 4
  • High Estimate -0.48
  • Low Estimate -0.61
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -31.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.52 +3.02%
on 08/03/20
87.25 -16.73%
on 07/09/20
-8.32 (-10.28%)
since 07/02/20
3-Month
69.77 +4.13%
on 06/12/20
94.10 -22.79%
on 05/08/20
-17.48 (-19.39%)
since 05/01/20
52-Week
13.64 +432.62%
on 10/01/19
109.94 -33.92%
on 12/30/19
+46.96 (+182.79%)
since 08/02/19

Most Recent Stories

More News
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020

Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time

AXSM : 74.75 (+4.79%)
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020

Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.

BMRN : 120.32 (+0.43%)
EBS : 118.00 (+6.08%)
AXSM : 74.75 (+4.79%)
UMRX : 2.62 (-2.60%)
Axsome's NDA for Depressive Disorder Drug on Track in Q420

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.

BMRN : 120.32 (+0.43%)
EBS : 118.00 (+6.08%)
AXSM : 74.75 (+4.79%)
UMRX : 2.62 (-2.60%)
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder

NDA submission on track for 4Q 2020

AXSM : 74.75 (+4.79%)
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS.

AXSM : 74.75 (+4.79%)
BIG : 39.51 (+0.43%)
DVAX : 8.22 (+1.36%)
DIS : 116.46 (-0.41%)
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer's Disease Agitation

Designation offers potential for expedited development and review

AXSM : 74.75 (+4.79%)
Notable Monday Option Activity: AXSM, PRLB, ECPG

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Axsome Therapeutics Inc , where a total of 2,538 contracts have traded so far, representing...

AXSM : 74.75 (+4.79%)
Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AXSM : 74.75 (+4.79%)
Axsome Therapeutics to Present at Upcoming Investor Conferences

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in two upcoming investor...

AXSM : 74.75 (+4.79%)
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI...

AXSM : 74.75 (+4.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade AXSM with:

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

2nd Resistance Point 76.52
1st Resistance Point 73.92
Last Price 74.75
1st Support Level 70.00
2nd Support Level 68.68

See More

52-Week High 109.94
Last Price 74.75
Fibonacci 61.8% 73.15
Fibonacci 50% 61.79
Fibonacci 38.2% 50.43
52-Week Low 13.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar